천식이 있는 12세~18세 미만 참가자에게 필요에 따라 투여되는 PT007과 비교하여 PT027의 효능 및 안전성 평가 (ACADIA)
천식을 앓고 있는 12세~18세 미만 참가자에게 필요에 따라 투여된 PT007과 비교하여 PT027의 유효성 및 안전성을 평가하는 무작위, 이중 맹검, 다기관, 병렬 그룹, 3b상 52주 연구(ACADIA)
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a randomized, double-blind, multicenter, parallel-group Phase IIIb study with a fixed treatment period of 52 weeks.
The study will consist of 3 periods:
- Screening period (7 to 28 days)
- Treatment period of 52 weeks
- Safety follow-up period (7 to 14 days after the end of treatment [EOT] visit)
Participants who meet the eligibility criteria will be randomly assigned to BDA MDI 160/180 micrograms (μg) or AS MDI 180 μg treatment groups in a 1:1 ratio on top of their own usual maintenance therapy during treatment period.
This study will also include a pharmacokinetic (PK) sub-study with single visit scheduled after the safety follow-up visit in the main study. During PK sub-study, single dose of open-label BDA MDI 160/180 μg will be administered.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: AstraZeneca Clinical Study Information Center
- 전화번호: 1-877-240-9479
- 이메일: information.center@astrazeneca.com
연구 장소
-
-
-
Durban, 남아프리카, 4001
- 모병
- Research Site
-
Durban, 남아프리카, 3630
- 모병
- Research Site
-
Durban, 남아프리카, 4092
- 모병
- Research Site
-
Krugersdorp, 남아프리카, 1739
- 모병
- Research Site
-
Middelburg, 남아프리카, 1055
- 모병
- Research Site
-
Panorama, 남아프리카, 7500
- 모병
- Research Site
-
Somerset West, 남아프리카, 7130
- 아직 모집하지 않음
- Research Site
-
Welkom, 남아프리카, 9460
- 모병
- Research Site
-
-
-
-
-
Chihuahua City, 멕시코, 31000
- 모병
- Research Site
-
Chihuahua City, 멕시코, 31238
- 모병
- Research Site
-
Guadalajara, 멕시코, 44100
- 모병
- Research Site
-
Guadalajara, 멕시코, 44500
- 모병
- Research Site
-
Monterrey, 멕시코, 64465
- 모병
- Research Site
-
-
-
-
Alaska
-
Anchorage, Alaska, 미국, 99508
- 모병
- Research Site
-
-
Arizona
-
Gilbert, Arizona, 미국, 85234
- 모병
- Research Site
-
Phoenix, Arizona, 미국, 85016
- 모병
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72202
- 완전한
- Research Site
-
-
California
-
Huntington Beach, California, 미국, 92647
- 아직 모집하지 않음
- Research Site
-
Huntington Beach, California, 미국, 92648
- 아직 모집하지 않음
- Research Site
-
Long Beach, California, 미국, 90806
- 모병
- Research Site
-
Long Beach, California, 미국, 90815
- 모병
- Research Site
-
Madera, California, 미국, 93636
- 아직 모집하지 않음
- Research Site
-
Mission Viejo, California, 미국, 92691
- 모병
- Research Site
-
Moreno Valley, California, 미국, 92553
- 모병
- Research Site
-
Orange, California, 미국, 92868
- 모병
- Research Site
-
Redondo Beach, California, 미국, 90277
- 모병
- Research Site
-
Riverside, California, 미국, 92506
- 모병
- Research Site
-
San Diego, California, 미국, 92123
- 아직 모집하지 않음
- Research Site
-
San Diego, California, 미국, 92123
- 모병
- Research Site
-
San Francisco, California, 미국, 94143
- 빼는
- Research Site
-
Westminster, California, 미국, 92683
- 모병
- Research Site
-
-
Colorado
-
Denver, Colorado, 미국, 80206
- 모병
- Research Site
-
-
Delaware
-
Wilmington, Delaware, 미국, 19803
- 모병
- Research Site
-
-
Florida
-
Destin, Florida, 미국, 32541
- 모병
- Research Site
-
Jacksonville, Florida, 미국, 32207
- 모병
- Research Site
-
Kendall, Florida, 미국, 33176
- 아직 모집하지 않음
- Research Site
-
Largo, Florida, 미국, 33777
- 완전한
- Research Site
-
Miami, Florida, 미국, 33144
- 모병
- Research Site
-
Miami, Florida, 미국, 33145
- 모병
- Research Site
-
Miami, Florida, 미국, 33185
- 모병
- Research Site
-
Miami, Florida, 미국, 33142
- 모병
- Research Site
-
Miami, Florida, 미국, 33183
- 모병
- Research Site
-
Orlando, Florida, 미국, 32827
- 아직 모집하지 않음
- Research Site
-
Pembroke Pines, Florida, 미국, 33026
- 모병
- Research Site
-
Tampa, Florida, 미국, 33613
- 빼는
- Research Site
-
-
Georgia
-
Atlanta, Georgia, 미국, 30329
- 모병
- Research Site
-
Columbus, Georgia, 미국, 31904
- 모병
- Research Site
-
Fayetteville, Georgia, 미국, 30214
- 모병
- Research Site
-
Snellville, Georgia, 미국, 30078
- 모병
- Research Site
-
-
Idaho
-
Meridian, Idaho, 미국, 83646
- 빼는
- Research Site
-
-
Illinois
-
Normal, Illinois, 미국, 61761
- 모병
- Research Site
-
River Forest, Illinois, 미국, 60305
- 빼는
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- 모병
- Research Site
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- 모병
- Research Site
-
Overland Park, Kansas, 미국, 66213
- 아직 모집하지 않음
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40217
- 모병
- Research Site
-
Louisville, Kentucky, 미국, 40202
- 모병
- Research Site
-
-
Louisiana
-
Lafayette, Louisiana, 미국, 70508
- 모병
- Research Site
-
New Orleans, Louisiana, 미국, 70121
- 모병
- Research Site
-
New Orleans, Louisiana, 미국, 70125
- 모병
- Research Site
-
-
Maryland
-
Ellicott City, Maryland, 미국, 21043
- 모병
- Research Site
-
Lanham, Maryland, 미국, 20706
- 아직 모집하지 않음
- Research Site
-
Silver Spring, Maryland, 미국, 20902
- 모병
- Research Site
-
White Marsh, Maryland, 미국, 21162
- 모병
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- 아직 모집하지 않음
- Research Site
-
-
Michigan
-
Detroit, Michigan, 미국, 48201
- 모병
- Research Site
-
-
Minnesota
-
Mankato, Minnesota, 미국, 56001
- 모집하지 않고 적극적으로
- Research Site
-
-
Missouri
-
Kansas City, Missouri, 미국, 64118
- 모병
- Research Site
-
Kansas City, Missouri, 미국, 64108
- 빼는
- Research Site
-
St Louis, Missouri, 미국, 63108
- 모병
- Research Site
-
-
Montana
-
Missoula, Montana, 미국, 59804
- 모병
- Research Site
-
-
Nebraska
-
Lincoln, Nebraska, 미국, 68510
- 모병
- Research Site
-
Lincoln, Nebraska, 미국, 68516
- 모병
- Research Site
-
Omaha, Nebraska, 미국, 68114
- 모병
- Research Site
-
-
New Jersey
-
Newark, New Jersey, 미국, 07103
- 모병
- Research Site
-
Newark, New Jersey, 미국, 07103
- 아직 모집하지 않음
- Research Site
-
Northfield, New Jersey, 미국, 08225
- 모병
- Research Site
-
Ocean City, New Jersey, 미국, 07712
- 모병
- Research Site
-
Paramus, New Jersey, 미국, 07652
- 모병
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87106
- 모병
- Research Site
-
-
New York
-
Albany, New York, 미국, 12208
- 모병
- Research Site
-
Cortland, New York, 미국, 13045
- 모병
- Research Site
-
Hawthorne, New York, 미국, 10532
- 모병
- Research Site
-
Hollis, New York, 미국, 11423
- 빼는
- Research Site
-
New York, New York, 미국, 10032
- 모병
- Research Site
-
New York, New York, 미국, 11355
- 모병
- Research Site
-
New York, New York, 미국, 10019
- 빼는
- Research Site
-
Rochester, New York, 미국, 14607
- 완전한
- Research Site
-
The Bronx, New York, 미국, 10459
- 모병
- Research Site
-
The Bronx, New York, 미국, 10461
- 모병
- Research Site
-
Vestal, New York, 미국, 13850
- 모병
- Research Site
-
Vestal, New York, 미국, 13850
- 빼는
- Research Site
-
Watertown, New York, 미국, 13601
- 모병
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28277
- 빼는
- Research Site
-
Durham, North Carolina, 미국, 27705
- 아직 모집하지 않음
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45229
- 아직 모집하지 않음
- Research Site
-
Columbus, Ohio, 미국, 43205
- 아직 모집하지 않음
- Research Site
-
Columbus, Ohio, 미국, 43228
- 모병
- Research Site
-
Dayton, Ohio, 미국, 45424
- 모병
- Research Site
-
Findlay, Ohio, 미국, 45840
- 모병
- Research Site
-
Toledo, Ohio, 미국, 43617
- 모병
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73120
- 모병
- Research Site
-
Oklahoma City, Oklahoma, 미국, 73104
- 모병
- Research Site
-
Oklahoma City, Oklahoma, 미국, 73104
- 아직 모집하지 않음
- Research Site
-
Yukon, Oklahoma, 미국, 73099
- 모병
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15241
- 모병
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- 모병
- Research Site
-
Rock Hill, South Carolina, 미국, 29730
- 완전한
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57105
- 모병
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37232
- 모병
- Research Site
-
-
Texas
-
Austin, Texas, 미국, 78759
- 모병
- Research Site
-
Baytown, Texas, 미국, 77521
- 모병
- Research Site
-
Beaumont, Texas, 미국, 77701
- 모병
- Research Site
-
Beaumont, Texas, 미국, 77702
- 모병
- Research Site
-
Bellaire, Texas, 미국, 77401
- 모병
- Research Site
-
Corpus Christi, Texas, 미국, 78411
- 모병
- Research Site
-
Corsicana, Texas, 미국, 75110
- 모병
- Research Site
-
Dallas, Texas, 미국, 75231
- 모병
- Research Site
-
Dallas, Texas, 미국, 75235
- 모병
- Research Site
-
El Paso, Texas, 미국, 79912
- 모병
- Research Site
-
Frisco, Texas, 미국, 75034
- 빼는
- Research Site
-
Houston, Texas, 미국, 77099
- 모병
- Research Site
-
Houston, Texas, 미국, 77030
- 아직 모집하지 않음
- Research Site
-
Houston, Texas, 미국, 77065
- 모병
- Research Site
-
Kerrville, Texas, 미국, 78028
- 빼는
- Research Site
-
McKinney, Texas, 미국, 75069
- 모병
- Research Site
-
San Antonio, Texas, 미국, 78229
- 모병
- Research Site
-
San Antonio, Texas, 미국, 78215
- 모병
- Research Site
-
San Antonio, Texas, 미국, 78249
- 아직 모집하지 않음
- Research Site
-
Tyler, Texas, 미국, 75708
- 완전한
- Research Site
-
-
Utah
-
West Jordan, Utah, 미국, 84088
- 모병
- Research Site
-
-
Vermont
-
Burlington, Vermont, 미국, 05405
- 모병
- Research Site
-
-
Virginia
-
Burke, Virginia, 미국, 22015
- 빼는
- Research Site
-
-
Washington
-
Bellingham, Washington, 미국, 98225
- 완전한
- Research Site
-
Vancouver, Washington, 미국, 98664
- 모병
- Research Site
-
-
-
-
-
Beijing, 중국, 100191
- 모병
- Research Site
-
Beijing, 중국, 100050
- 모병
- Research Site
-
Bengbu, 중국, 233004
- 모병
- Research Site
-
Chengdu, 중국, 610066
- 모병
- Research Site
-
Chongqing, 중국, 401122
- 모병
- Research Site
-
Hohhot, 중국, 10050
- 모병
- Research Site
-
Mianyang, 중국, 621000
- 모병
- Research Site
-
Shanghai, 중국, 200433
- 모병
- Research Site
-
Shanghai, 중국
- 모병
- Research Site
-
Shanghai, 중국, 200062
- 모병
- Research Site
-
Shantou, 중국, 515041
- 모병
- Research Site
-
Shenyang, 중국, 110004
- 모병
- Research Site
-
Shenzhen, 중국, 518026
- 모병
- Research Site
-
Suzhou, 중국, 215002
- 모병
- Research Site
-
Taizhou, 중국, 318000
- 모병
- Research Site
-
Tianjin, 중국, 300211
- 모병
- Research Site
-
Tianjin, 중국, 300134
- 모병
- Research Site
-
Tianjin, 중국, 300050
- 모병
- Research Site
-
Wuhan, 중국, 430000
- 모병
- Research Site
-
Yanji, 중국, 133000
- 모병
- Research Site
-
Yantai, 중국, 264000
- 모병
- Research Site
-
Zhongshan, 중국, 528400
- 모병
- Research Site
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Confirmed clinical diagnosis of asthma at least 12 months.
-
Receiving one of the following scheduled asthma maintenance therapies for at least 3 months with stable dosing for at least the last one month
- Low-to-high-dose Inhaled corticosteroid(s) (ICS)
- Low-to-high-dose ICS or ICS/long-acting β2-agonist (LABA) with or without one additional maintenance therapy from the following: leukotriene receptor antagonist (LTRA), long-acting muscarinic antagonist (LAMA), or theophylline
-
Receiving inhaled short-acting β2-agonist (SABA) as needed.
-
A documented history of at least one severe asthma exacerbation within 12 months.
-
Use of Sponsor-provided albuterol sulfate inhalation aerosol medication.
-
Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited.
-
Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as assessed by the investigator.
-
Participants must adhere to protocol specific contraception methods.
-
Negative urine pregnancy test for participants of childbearing potential.
-
Have a BMI < 40 kg/ m^2.
-
Capable of giving assent (signing the assent form) to participate in the study which includes compliance with the requirements and restrictions. The caregiver of the patient must be capable of giving written informed consent for the patient's participation in the study. Consent and assent forms must be completed prior to any study-specific procedures.
Exclusion Criteria:
- Life-threatening asthma defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).
- Experienced > 3 severe asthma exacerbations within 12 months before screening.
- Completed treatment for lower respiratory infection and severe asthma exacerbation with SCS within 4 weeks of screening.
- Upper respiratory infection involving antibiotic treatment not resolved.
- Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking < 6 months (including all forms of tobacco, e-cigarettes [vaping], and marijuana).
- Other significant lung disease, including regular or occasional use of oxygen.
- Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, hematological, neuropsychological, endocrine, or gastrointestinal disorders.
- Cancer not in complete remission for at least 5 years.
- History or hospitalization for psychiatric disorder or attempted suicide within one year.
- Significant abuse of alcohol or drugs, in the opinion of the investigator.
- Oral corticosteroid(s) (OCS)/SCS use (any dose and any indication) within 4 weeks before Visit 1 or chronic use of OCS/SCS (≥ 3 weeks use in 3 months prior to Visit 1).
- Use of any oral SABAs within one month.
- Having a known or suspected hypersensitivity to albuterol/salbutamol, or budesonide and/or their excipients.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Budesonide/albuterol metered -dose inhaler (BDA MDI)
Participants will receive BDA MDI 160/180 μg (given as 2 puffs of 80/90 μg) as needed. |
Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.
다른 이름들:
|
|
활성 비교기: Albuterol sulfate metered-dose inhaler (AS MDI)
Participants will receive AS MDI 180 μg (given as 2 puffs of 90 μg) as needed. |
Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Annualized rate of severe asthma exacerbations (AAER)
기간: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the AAER in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to first (TTF) severe asthma exacerbation
기간: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the risk of a first severe asthma exacerbation in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
|
Annualized total systemic corticosteroids (SCS) exposure for treatment of asthma
기간: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the annualized total SCS exposure for treatment of asthma in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
|
Number of participants with adverse events (AEs) and severe adverse events (SAEs)
기간: Up to Week 52
|
The safety and tolerability of BDA MDI compared with AS MDI in participants with asthma will be assessed. |
Up to Week 52
|
|
Maximum Observed Concentration (Cmax)
기간: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Area under concentration-time curve from time 0 to last quantifiable concentration (AUClast)
기간: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Area under concentration-time curve from time 0 to infinity (AUCinf)
기간: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Time to reach maximum concentration following drug administration (Tmax)
기간: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Time of last quantifiable concentration (Tlast)
기간: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Terminal elimination half-life (t½λz)
기간: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Terminal elimination rate constant (λz)
기간: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Apparent total body clearance (CL/F)
기간: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Apparent volume of distribution based on the terminal phase (Vz/F)
기간: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- D6934C00001
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD 공유 기간
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 공유 액세스 기준
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non negotiable contract for data accessors) must be in place before accessing requested information.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .